Saturday, February 24, 2024
CEOWORLD magazine - Latest - CEO Spotlight - Michael Dattoli Offers a New Therapeutic Agent for Advanced Prostate Cancer

CEO Spotlight

Michael Dattoli Offers a New Therapeutic Agent for Advanced Prostate Cancer

This week Dattoli Cancer Center & Brachytherapy Research Institute became the first independent physician practice in the U.S. to offer men with advanced metastatic prostate cancer an injectable isotope of radium, marketed by Bayer as Xofigo® (zoh-fee-go).  This new pharmaceutical was recently FDA approved for use in men with castration-resistant prostate cancer (CRPC), which means their cancer has spread to bones.

Consisting of Radium Ra 223 dichloride, the drug is administered as an injection once a month, for 6 treatments.  Xofigo® reacts similarly to calcium in bonding with bone lesions caused by the metastasis of prostate cancer.  Xofigo® has been found to improve survival rates by 30% while treating symptomatic bone pain.  While not curative, this therapy is an improvement over more prolonged treatments such as chemotherapy with far fewer side effects.

The professionals at Dattoli Cancer Center note that metastatic prostate cancer occurs when the disease goes untreated or may be insufficiently treated, and cancer moves outside the prostate capsule.  The disease frequently manifests itself as painful lesions in the bone, particularly the hip, spine, ribs, and scapula.  It can also attack other organs such as the lungs and brain.  It is estimated that as many as 20,000 American men will advance to castration-resistant prostate cancer in any one year.

Unlike Radium RA 226, discovered by the Curies at the beginning of the 20th Century, the radioactive power of Radium Ra 223 is manageable in the 21st Century.  RA 226 which was “discovered” in 1903 is still emitting radiation – its half-life being 1,601 years.  In contrast, Ra 223 has a half-life of just over 11 days.

The Dattoli Cancer Center has constructed an on-site “hot lab” to contain Xofigo® overnight.  The injections are ordered for individual patients and delivered to the Center for administration. Because the Ra 223 is active when it arrives, it must be stored, even temporarily, in specifically designed radiation-safe containers and surroundings.

Xofigo® will be covered by Medicare and most major health insurance policies.

Dattoli Cancer Center was established in 2000 and is known internationally for its non-surgical treatment protocol for prostate cancer.  The Center has the longest, peer-reviewed published prostate cancer cure rate in the world.

Have you read?
Best Business Schools In The World For 2022.
Best Fashion Schools In The World For 2022.
Best Hospitality And Hotel Management Schools In The World For 2022.
Best Medical Schools In The World For 2022.
The World’s Best Universities For Doctor of Business Administration (DBA), 2022.

Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Thank you for supporting our journalism. Subscribe here.
For media queries, please contact:
CEOWORLD magazine - Latest - CEO Spotlight - Michael Dattoli Offers a New Therapeutic Agent for Advanced Prostate Cancer
Anna Papadopoulos
Anna Papadopoulos is a senior money, wealth, and asset management reporter at CEOWORLD magazine, covering consumer issues, investing and financial communities + author of the CEOWORLD magazine newsletter, writing about money with an enthusiasm unknown to mankind. You can follow CEOWORLD magazine on Twitter, Facebook, Instagram, or connect on LinkedIn for musings on money, wealth, asset management, millionaires, and billionaires. Email her at